

Supplementary file 1: Search strategy

((COVID-19 OR Corona Virus Disease OR SARS CoV 2) AND (RCT OR Randomized Controlled Trial OR Randomised Controlled Trial)) AND (Vaccine OR Vaccines) (((COVID-19 OR Corona Virus Disease OR SARS CoV 2) AND (RCT OR Randomized Controlled Trial OR Randomised Controlled Trial))) AND (Drug)

Supplementary file 2: List of Articles used for this review

1. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2021801>
2. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2033130>
3. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18–59 years: An interim analysis in Indonesia - ScienceDirect (n.d.). Retrieved April 26, 2023, from <https://www.sciencedirect.com/science/article/pii/S0264410X2101255X>
4. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics | Nature Communications (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41467-020-19056-6>
5. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment of Severe COVID-19 | Antimicrobial Agents and Chemotherapy (n.d.). Retrieved April 26, 2023, from <https://journals.asm.org/doi/full/10.1128/AAC.01061-20>
6. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/nejmoa2016638>
7. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>
8. Abd-Elsalam, S, Esmail, ES, Khalaf, M, ... Alborai, M (2020) Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *The American Journal of Tropical Medicine and Hygiene*, **103**(4), 1635–1639. doi:10.4269/ajtmh.20-0873.
9. Abdulmir, AS, Gorial, FI, Saadi, SJ, ... abdulrazaq, MK (2021) A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management. *Annals of Medicine and Surgery*, **69**, 102779. doi:10.1016/j.amsu.2021.102779.
10. Ader, F (2020) Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. *BMJ Open*, **10**(9), e041437. doi:10.1136/bmjopen-2020-041437.
11. Ahmed, S, Karim, MM, Ross, AG, ... Khan, WA (2021) A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. *International Journal of Infectious Diseases*, **103**, 214–216. doi:10.1016/j.ijid.2020.11.191.
12. Alavi Darazam, I, Hatami, F, Mahdi Rabiei, M, ... Shafigh, N (2021) An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. *International Immunopharmacology*, **99**, 107916. doi:10.1016/j.intimp.2021.107916.
13. Algahtani, FD, Elabbasy, MT, Samak, MA, Adeboye, AA, Yusuf, RA, and Ghoniem, ME (2021) The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study. *Medicina*, **57**(8), 842. doi:10.3390/medicina57080842.

14. Aman, J, Duijvelaar, E, Botros, L, ... Bogaard, HJ (2021) Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. *The Lancet Respiratory Medicine*, **9**(9), 957–968. doi:10.1016/S2213-2600(21)00237-X.
15. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2022483>
16. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients | Scientific Reports (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41598-021-88509-9>
17. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial - Brett L Houston, Patrick R Lawler, Ewan C Goligher, Michael E Farkouh, Charlotte Bradbury, Marc Carrier, Vlad Dzavik, Dean A Fergusson, Robert A Fowler, Jean-Phillippe Galanaud, Peter L Gross, Emily G McDonald, Mansoor Husain, Susan R Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S Slutsky, Alexis F Turgeon, Scott M Berry, Robert S Rosenson, Jorge Escobedo, Jose C Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski, 2020 (n.d.). Retrieved April 26, 2023, from https://journals.sagepub.com/doi/full/10.1177/1740774520943846?casa_token=_OfMKIH0Vx8AAA%3AKfKzuzemUE1Z_vw2kj6U5xnF9CmbP7ID0b1bjeJW2lbuPZPEutE7Puka_pPi68s919IoLC2LsfjIF8OG
18. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2031994>
19. Bauer, A, Schreinlechner, M, Sappeler, N, ... Zabernigg, A (2021) Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. *The Lancet Respiratory Medicine*, **9**(8), 863–872. doi:10.1016/S2213-2600(21)00214-9.
20. BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial) | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/10/e052101.abstract>
21. Beigel, JH, Tomashek, KM, Dodd, LE, ... Lane, HC (2020) Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine*, **383**(19), 1813–1826. doi:10.1056/NEJMoa2007764.
22. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial | RMD Open (n.d.). Retrieved April 26, 2023, from <https://rmdopen.bmj.com/content/7/1/e001455.abstract>
23. Borba, MGS, Val, FFA, Sampaio, VS, ... for the CloroCovid-19 Team (2020) Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Network Open*, **3**(4), e208857. doi:10.1001/jamanetworkopen.2020.8857.
24. Bosi, E, Bosi, C, Rovere Querini, P, ... Bregni, M (2020) Interferon β -1a (IFN β -1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. *Trials*, **21**(1), 939. doi:10.1186/s13063-020-04864-4.

25. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study - Li - 2020 - Clinical and Translational Science - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12881>
26. Butler, CC, Dorward, J, Yu, L-M, ... Hobbs, FR (2021) Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *The Lancet*, **397**(10279), 1063–1074. doi:10.1016/S0140-6736(21)00461-X.
27. Cao, Y, Wei, J, Zou, L, ... Zhou, J (2020) Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *Journal of Allergy and Clinical Immunology*, **146**(1), 137-146.e3. doi:10.1016/j.jaci.2020.05.019.
28. Casey, JD, Johnson, NJ, Semler, MW, ... Self, WH (2020) Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. *Annals of the American Thoracic Society*, **17**(9), 1144–1153. doi:10.1513/AnnalsATS.202005-478SD.
29. Chappell, KJ, Mordant, FL, Li, Z, ... Munro, TP (2021) Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. *The Lancet Infectious Diseases*, **21**(10), 1383–1394. doi:10.1016/S1473-3099(21)00200-0.
30. Chen, C, Zhang, Y, Huang, J, ... Wang, X (2021) Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. *Frontiers in Pharmacology*, **12**. Retrieved from <https://www.frontiersin.org/articles/10.3389/fphar.2021.683296>
31. Chen, C-P, Lin, Y-C, Chen, T-C, ... Group, on behalf of the THS (2020) A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PLOS ONE*, **15**(12), e0242763. doi:10.1371/journal.pone.0242763.
32. Cheng, L, Guan, W, Duan, C, ... Zhong, N (2021) Effect of Recombinant Human Granulocyte Colony–Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. *JAMA Internal Medicine*, **181**(1), 71–78. doi:10.1001/jamainternmed.2020.5503.
33. Chu, L, McPhee, R, Huang, W, ... Leav, B (2021) A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine*, **39**(20), 2791–2799. doi:10.1016/j.vaccine.2021.02.007.
34. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study - Abd-El Salam - 2021 - Journal of Medical Virology - Wiley Online Library (n.d.). Retrieved April 26, 2023, from https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27122?casa_token=h3yw5_sJfEgAAAAA:_WooYbWE6s5angYKVOr1QjWyumGu-Ob7ImHe4vzk2JzL3galzDq1Kq4zRsfX0XdH41k_tpUChGzCaiT

35. Cohen, MS, Nirula, A, Mulligan, MJ, ... BLAZE-2 Investigators (2021) Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. *JAMA*, **326**(1), 46–55. doi:10.1001/jama.2021.8828.
36. Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19 - Altay - 2021 - Advanced Science - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202101222>
37. Dabbous, HM, Abd-Elsalam, S, El-Sayed, MH, ... Tageldin, MA (2021a) RETRACTED ARTICLE: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. *Archives of Virology*, **166**(3), 949–954. doi:10.1007/s00705-021-04956-9.
38. Dabbous, HM, El-Sayed, MH, El Assal, G, ... TagelDin, MA (2021b) RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. *Scientific Reports*, **11**(1), 7282. doi:10.1038/s41598-021-85227-0.
39. Davoodi, L, Abedi, SM, Salehifar, E, ... Hosseinimehr, SJ (2020) Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. *International Journal of Clinical Practice*, **74**(11), e13600. doi:10.1111/ijcp.13600.
40. de Alencar, JCG, Moreira, C de L, Müller, AD, ... COVID Register Group (2021) Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases*, **72**(11), e736–e741. doi:10.1093/cid/ciaa1443.
41. Dubée, V, Roy, P-M, Vielle, B, ... Eeckhoutte, L van (2021) Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. *Clinical Microbiology and Infection*, **27**(8), 1124–1130. doi:10.1016/j.cmi.2021.03.005.
42. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial | Global Health | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2780562>
43. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial | BMC Infectious Diseases | Full Text (n.d.). Retrieved April 26, 2023, from <https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w>
44. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2782185>
45. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2775280>
46. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial | Infectious Diseases | JAMA Network Open | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2779044>

47. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2770276>
48. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 (2020) *New England Journal of Medicine*, **383**(21), 2030–2040. doi:10.1056/NEJMoa2022926.
49. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2777829>
50. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial | Infectious Diseases | JAMA | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jama/article-abstract/2782166>
51. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study - Kosiborod - 2021 - Diabetes, Obesity and Metabolism - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14296>
52. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial | Infectious Diseases | JAMA Internal Medicine | JAMA Network (n.d.). Retrieved April 26, 2023, from <https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2771265>
53. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial | SpringerLink (n.d.). Retrieved April 26, 2023, from <https://link.springer.com/article/10.1186/s12879-021-05983-2>
54. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial | Journal of Antimicrobial Chemotherapy | Oxford Academic (n.d.). Retrieved April 26, 2023, from <https://academic.oup.com/jac/article/76/8/2158/6284235>
55. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/nejmoa2035389>
56. Efficacy and tolerability of bevacizumab in patients with severe Covid-19 | Nature Communications (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41467-021-21085-8>
57. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil | Nature Communications (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41467-021-25982-w>
58. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study | SpringerLink (n.d.). Retrieved April 26, 2023, from <https://link.springer.com/article/10.1186/s13063-020-04478-w>
59. Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial

- (CAME COVID-19 study) | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/9/e053325.abstract>
60. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2103055>
 61. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2102214>
 62. Ella, R, Vadrevu, KM, Jogdand, H, ... Bhargava, B (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *The Lancet Infectious Diseases*, **21**(5), 637–646. doi:10.1016/S1473-3099(20)30942-7.
 63. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial: *Annals of Internal Medicine: Vol 174, No 9* (n.d.). Retrieved April 26, 2023, from <https://www.acpjournals.org/doi/full/10.7326/M21-0653>
 64. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial | *Journal of Antimicrobial Chemotherapy* | Oxford Academic (n.d.). Retrieved April 26, 2023, from <https://academic.oup.com/jac/article/75/11/3373/5889947>
 65. Fakharian, A, Barati, S, Mirenayat, M, ... Dastan, F (2021) Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial. *International Immunopharmacology*, **99**, 107961. doi:10.1016/j.intimp.2021.107961.
 66. Feld, JJ, Kandel, C, Biondi, MJ, ... Hansen, BE (2021) Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. *The Lancet Respiratory Medicine*, **9**(5), 498–510. doi:10.1016/S2213-2600(20)30566-X.
 67. Folegatti, PM, Ewer, KJ, Aley, PK, ... Yau, Y (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*, **396**(10249), 467–478. doi:10.1016/S0140-6736(20)31604-4.
 68. Full article: A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19 (n.d.). Retrieved April 26, 2023, from <https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1905794>
 69. Furtado, RHM, Berwanger, O, Fonseca, HA, ... Cavalcanti, AB (2020) Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *The Lancet*, **396**(10256), 959–967. doi:10.1016/S0140-6736(20)31862-6.
 70. Galan, LEB, Santos, NM dos, Asato, MS, ... da Fonseca, AJ (2021) Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. *Pathogens and Global Health*, **115**(4), 235–242. doi:10.1080/20477724.2021.1890887.
 71. Ghandehari, S, Matusov, Y, Pepkowitz, S, ... Lewis, M (2021) Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe

- COVID-19: A Randomized, Controlled Pilot Trial. *Chest*, **160**(1), 74–84. doi:10.1016/j.chest.2021.02.024.
72. Goepfert, PA, Fu, B, Chabanon, A-L, ... de Bruyn, G (2021) Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. *The Lancet Infectious Diseases*, **21**(9), 1257–1270. doi:10.1016/S1473-3099(21)00147-X.
73. Goldman, JD, Lye, DCB, Hui, DS, ... Subramanian, A (2020) Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *New England Journal of Medicine*, **383**(19), 1827–1837. doi:10.1056/NEJMoa2015301.
74. Gonzalez-Ochoa, AJ, Raffetto, JD, Hernández, AG, ... Loustaunau, J (2020, December 7) Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial., medRxiv, , 2020.12.04.20242073. doi:10.1101/2020.12.04.20242073.
75. Gyselinck, I, Liesenborghs, L, Landeloos, E, ... on behalf of the DAWn-Azithro consortium (2021) Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial. *Trials*, **22**(1), 126. doi:10.1186/s13063-021-05033-x.
76. Hamed, DM, Belhouli, KM, Al Maazmi, NA, ... AbdulRahman, M (2021) Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison. *Journal of Infection and Public Health*, **14**(8), 985–989. doi:10.1016/j.jiph.2021.06.003.
77. Hermine, O, Mariette, X, Tharaux, P-L, ... CORIMUNO-19 Collaborative Group (2021) Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine*, **181**(1), 32–40. doi:10.1001/jamainternmed.2020.6820.
78. Hernandez-Cardenas, C, Thirion-Romero, I, Rodríguez-Llamazares, S, ... Covid-19, on behalf of the RG on hydroxychloroquine for (2021) Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial. *PLOS ONE*, **16**(9), e0257238. doi:10.1371/journal.pone.0257238.
79. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan - Munch - 2021 - Acta Anaesthesiologica Scandinavica - Wiley Online Library (n.d.). Retrieved April 26, 2023, from https://onlinelibrary.wiley.com/doi/abs/10.1111/aas.13795?casa_token=7oF03IIWpYoAAAAA:ATsK1V165tEvACckdcAQ1XmAugoGALlyT9_-dUsLqKDr2NQunk82BAEN3_nDHHo3nwOj-mUDV9aJNqlo
80. Hinks, TSC, Cureton, L, Knight, R, ... Richards, D (2021) Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. *The Lancet Respiratory Medicine*, **9**(10), 1130–1140. doi:10.1016/S2213-2600(21)00263-0.
81. Huang, Y-Q, Tang, S-Q, Xu, X-L, ... Chen, Y-K (2020) No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. *Frontiers in Pharmacology*, **11**. Retrieved from <https://www.frontiersin.org/articles/10.3389/fphar.2020.01071>

82. Hung, IF-N, Lung, K-C, Tso, EY-K, ... Yuen, K-Y (2020) Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet*, **395**(10238), 1695–1704. doi:10.1016/S0140-6736(20)31042-4.
83. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial: *Annals of Internal Medicine*: Vol 174, No 3 (n.d.). Retrieved April 26, 2023, from <https://www.acpjournals.org/doi/full/10.7326/M20-6519>
84. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial - *eClinicalMedicine* (n.d.). Retrieved April 26, 2023, from [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(21\)00053-5/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00053-5/fulltext)
85. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 | *NEJM* (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2019014>
86. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - *ScienceDirect* (n.d.). Retrieved April 26, 2023, from https://www.sciencedirect.com/science/article/pii/S0140673621014203?casa_token=9vKvihjAloMAAAAA:V80kY7AUWP-9Xlrt4W4RGQivzspmSG5TxQPnxRXsDBnzG4uvJi6m6nUobCacXGLATr-Ap1n8b5hi
87. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial | *Chinese Medical Journal* (n.d.). Retrieved April 26, 2023, from <https://mednexus.org/doi/full/10.1097/CM9.0000000000001702>
88. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials | *Chinese Medical Journal* (n.d.). Retrieved April 26, 2023, from <https://mednexus.org/doi/full/10.1097/CM9.0000000000001573>
89. impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 | *Journal of Antimicrobial Chemotherapy* | *Oxford Academic* (n.d.). Retrieved April 26, 2023, from <https://academic.oup.com/jac/article/75/11/3366/5889946>
90. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2 | *Cell Research* (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41422-021-00531-8>
91. Iturriaga, C, Eiffler, N, Aniba, R, ... Garcia-Huidobro, D (2021) A cluster randomized trial of interferon β -1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). *BMC Infectious Diseases*, **21**(1), 814. doi:10.1186/s12879-021-06519-4.
92. Ivashchenko, AA, Dmitriev, KA, Vostokova, NV, ... Ivachtchenko, AV (2021) AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clinical Infectious Diseases*, **73**(3), 531–534. doi:10.1093/cid/ciaa1176.

93. Jamaati, H, Hashemian, SM, Farzanegan, B, ... Dastan, F (2021) No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. *European Journal of Pharmacology*, **897**, 173947. doi:10.1016/j.ejphar.2021.173947.
94. Keech, C, Albert, G, Cho, I, ... Glenn, GM (2020) Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *New England Journal of Medicine*, **383**(24), 2320–2332. doi:10.1056/NEJMoa2026920.
95. Kosiborod, MN, Esterline, R, Furtado, RHM, ... Berwanger, O (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Diabetes & Endocrinology*, **9**(9), 586–594. doi:10.1016/S2213-8587(21)00180-7.
96. Lasky, JA, Fuloria, J, Morrison, ME, ... Melemed, A (2021) Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. *Advances in Therapy*, **38**(1), 782–791. doi:10.1007/s12325-020-01539-z.
97. Lemos, ACB, do Espírito Santo, DA, Salvetti, MC, ... Miranda, CH (2020) Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thrombosis Research*, **196**, 359–366. doi:10.1016/j.thromres.2020.09.026.
98. Lenze, EJ, Mattar, C, Zorumski, CF, ... Reiersen, AM (2020) Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA*, **324**(22), 2292–2300. doi:10.1001/jama.2020.22760.
99. Li, Y, Xie, Z, Lin, W, ... Li, L (2020, April 15) An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)., medRxiv, , 2020.03.19.20038984. doi:10.1101/2020.03.19.20038984.
100. Liesenborghs, L, Spriet, I, Jochmans, D, ... Verhamme, P (2021) Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. *EBioMedicine*, **66**, 103288. doi:10.1016/j.ebiom.2021.103288.
101. Liu, X, Shaw, RH, Stuart, ASV, ... Allen, L (2021) Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *The Lancet*, **398**(10303), 856–869. doi:10.1016/S0140-6736(21)01694-9.
102. Logunov, DY, Dolzhikova, IV, Shcheblyakov, DV, ... Gintsburg, AL (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *The Lancet*, **397**(10275), 671–681. doi:10.1016/S0140-6736(21)00234-8.
103. López-Medina, E, López, P, Hurtado, IC, ... Caicedo, I (2021) Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. *JAMA*, **325**(14), 1426–1435. doi:10.1001/jama.2021.3071.
104. Lou, Y, Liu, L, Yao, H, ... Qiu, Y (2021) Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. *European Journal of Pharmaceutical Sciences*, **157**, 105631. doi:10.1016/j.ejps.2020.105631.

105. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial—Protocol and statistical analysis plan - Petersen - 2020 - *Acta Anaesthesiologica Scandinavica* - Wiley Online Library (n.d.). Retrieved April 26, 2023, from https://onlinelibrary.wiley.com/doi/abs/10.1111/aas.13673?casa_token=RdGuQ__RH2QAAAAA:8kQABtChXgnvNBLzDCVNU6julZFaeDNjDWu9JtLsnJidu5PKKW-rehSRfhqqINpwzKsY8EOrxdaq9uVE
106. Maldonado, V, Hernandez-Ramírez, C, Oliva-Pérez, EA, ... Loza-Mejía, MA (2021) Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. *International Immunopharmacology*, **90**, 107209. doi:10.1016/j.intimp.2020.107209.
107. Mansour, E, Bueno, FF, de Lima-Júnior, JC, ... Velloso, LA (2021) Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. *Trials*, **22**(1), 71. doi:10.1186/s13063-021-05027-9.
108. Mohan, A, Tiwari, P, Suri, TM, ... Guleria, R (2021) Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial. *Journal of Infection and Chemotherapy*, **27**(12), 1743–1749. doi:10.1016/j.jiac.2021.08.021.
109. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19 | *BMJ Open* (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/4/e047495.abstract>
110. Nanni, CL, Annibale Biggeri, Chiara Zingaretti, Bernadette Vertogen, Valeria Frassinetti, Roberto Vespignani, Veruska Grossi, Caterina Florescu, Laura Matteucci, Chiara Pazzi, Alberto Bongiovanni, Francesco Limarzi, Valentina Fausti, Lucia Bertoni, Caterina Donati, Francesca Galardi, Nicola Gentili, Francesco Mazza, Giovanni Martinelli, Oriana (n.d.) Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. Retrieved April 26, 2023, from <https://epiprev.it/5563>
111. New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial) | *BMJ Open* (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/8/e045190.abstract>
112. Nouri-Vaskeh, M, Kalami, N, Zand, R, ... Sharifi, A (2021) Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial. *International Journal of Clinical Practice*, **75**(6), e14124. doi:10.1111/ijcp.14124.
113. Okumuş, N, Demirtürk, N, Çetinkaya, RA, ... Taşkın, G (2021) Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. *BMC Infectious Diseases*, **21**(1), 411. doi:10.1186/s12879-021-06104-9.
114. Panda, PK, Singh, BO, Moirangthem, B, ... Kant, R (2021) Antiviral Combination Clinically Better Than Standard Therapy in Severe but Not in Non-Severe COVID-19. *Clinical Pharmacology: Advances and Applications*, **13**, 185–195. doi:10.2147/CPAA.S325083.
115. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial | *Nature Communications* (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41467-021-22177-1>

116. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults | Nature (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41586-020-2639-4>
117. Pinzón, MA, Ortiz, S, Holguín, H, ... Ramirez, Z (2021) Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. *PLOS ONE*, **16**(5), e0252057. doi:10.1371/journal.pone.0252057.
118. Pu, J, Yu, Q, Yin, Z, ... Li, Q (2021) The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18–59 years: A phase I randomized, double-blinded, controlled trial. *Vaccine*, **39**(20), 2746–2754. doi:10.1016/j.vaccine.2021.04.006.
119. Rahmani, H, Davoudi-Monfared, E, Nourian, A, ... Yekaninejad, MS (2020) Interferon β -1b in treatment of severe COVID-19: A randomized clinical trial. *International Immunopharmacology*, **88**, 106903. doi:10.1016/j.intimp.2020.106903.
120. Rajasingham, R, Bangdiwala, AS, Nicol, MR, ... COVID PREP team (2021) Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. *Clinical Infectious Diseases*, **72**(11), e835–e843. doi:10.1093/cid/ciaa1571.
121. Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/5/e047069.abstract>
122. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol - Cohen - 2020 - The Journal of Clinical Hypertension - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://onlinelibrary.wiley.com/doi/full/10.1111/jch.14011>
123. Ranjbar, K, Moghadami, M, Mirahmadizadeh, A, ... Gholampoor Saadi, MH (2021) Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. *BMC Infectious Diseases*, **21**(1), 337. doi:10.1186/s12879-021-06045-3.
124. RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial | Scientific Reports (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41598-021-85227-0>
125. Richmond, P, Hatchuel, L, Dong, M, ... Clemens, R (2021) Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. *The Lancet*, **397**(10275), 682–694. doi:10.1016/S0140-6736(21)00241-5.
126. Rocco, PRM, Silva, PL, Cruz, FF, ... Silva, JRL e (2021) Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial. *European Respiratory Journal*, **58**(1). doi:10.1183/13993003.03725-2020.
127. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial | Scientific Reports (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41598-021-86859-y>
128. Roozbeh, F, Saeedi, M, Alizadeh-Navaei, R, ... Shamshirian, A (2021) Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. *Journal of Antimicrobial Chemotherapy*, **76**(3), 753–757. doi:10.1093/jac/dkaa501.

129. Rosas, IO, Bräu, N, Waters, M, ... Malhotra, A (2021) Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *New England Journal of Medicine*, **384**(16), 1503–1516. doi:10.1056/NEJMoa2028700.
130. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial | Signal Transduction and Targeted Therapy (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41392-021-00603-6>
131. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2107659>
132. Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/nejmoa2101544>
133. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials | Signal Transduction and Targeted Therapy (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41392-021-00692-3>
134. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 | SpringerLink (n.d.). Retrieved April 26, 2023, from <https://link.springer.com/article/10.1007/s00508-021-01922-y>
135. Salvarani, C, Dolci, G, Massari, M, ... RCT-TCZ-COVID-19 Study Group (2021) Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Internal Medicine*, **181**(1), 24–31. doi:10.1001/jamainternmed.2020.6615.
136. Samaha, AA, Mouawia, H, Fawaz, M, ... Raad, H (2021) Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon. *Viruses*, **13**(6), 989. doi:10.3390/v13060989.
137. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2029849>
138. Schwartz, I, Boesen, ME, Cerchiaro, G, ... Hill, MD (2021) Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *Canadian Medical Association Open Access Journal*, **9**(2), E693–E702. doi:10.9778/cmajo.20210069.
139. SciELO - Brazil - Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS) Justificativa e delineamento do estudo “Tocilizumabe em pacientes com COVID-19 moderado a grave: estudo aberto, multicêntrico, randomizado, controlado” (TOCIBRAS) (n.d.). Retrieved April 26, 2023, from <https://www.scielo.br/j/rbti/a/KzmQ33srPtCkV445mjhPznJ/abstract/?lang=en>
140. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab | Scientific Reports (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41598-021-88086-x>
141. Siami, Z, Aghajanian, S, Mansouri, S, ... Mozhgani, S-H (2021) Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized

- clinical trial. *International Journal of Infectious Diseases*, **108**, 306–308. doi:10.1016/j.ijid.2021.04.043.
142. Sivapalan, P, Ulrik, CS, Lappere, TS, ... Jensen, J-US (2020) Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. *Trials*, **21**(1), 867. doi:10.1186/s13063-020-04795-0.
143. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial | *Journal of Antimicrobial Chemotherapy* | Oxford Academic (n.d.). Retrieved April 26, 2023, from <https://academic.oup.com/jac/article/75/11/3379/5889948>
144. Soin, AS, Kumar, K, Choudhary, NS, ... Ramanan, AV (2021) Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. *The Lancet Respiratory Medicine*, **9**(5), 511–521. doi:10.1016/S2213-2600(21)00081-3.
145. Solaymani-Dodaran, M, Ghanei, M, Bagheri, M, ... Moazen, J (2021) Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *International Immunopharmacology*, **95**, 107522. doi:10.1016/j.intimp.2021.107522.
146. Spinner, CD, Gottlieb, RL, Criner, GJ, ... for the GS-US-540-5774 Investigators (2020) Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*, **324**(11), 1048–1057. doi:10.1001/jama.2020.16349.
147. Stone, JH, Frigault, MJ, Serling-Boyd, NJ, ... Mansour, MK (2020) Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *New England Journal of Medicine*, **383**(24), 2333–2344. doi:10.1056/NEJMoa2028836.
148. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 | *NEJM* (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2109682>
149. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial | *Nature Medicine* (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41591-020-01194-5>
150. Tabarsi, P, Barati, S, Jamaati, H, ... Dastan, F (2021) Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. *International Immunopharmacology*, **90**, 107205. doi:10.1016/j.intimp.2020.107205.
151. Tan, DHS, Chan, AK, Jüni, P, ... McGeer, A (2021) Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. *Trials*, **22**(1), 224. doi:10.1186/s13063-021-05134-7.
152. Tang, W, Cao, Z, Han, M, ... Xie, Q (2020) Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*, **369**, m1849. doi:10.1136/bmj.m1849.
153. Tang, X, Feng, Y-M, Ni, J-X, ... Sun, B (2021) Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial. *Respiration*, **100**(2), 116–126. doi:10.1159/000512063.

154. Tanriover, MD, Doğanay, HL, Akova, M, ... Aksu, K (2021) Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The Lancet*, **398**(10296), 213–222. doi:10.1016/S0140-6736(21)01429-X.
155. Tavares, M, Farraia, M, Silva, S, ... Moreira, A (2021) Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial. *Porto Biomedical Journal*, **6**(2), e134.1-5. doi:10.1097/j.pbj.000000000000134.
156. Tharoux, P-L, Pialoux, G, Pavot, A, ... Renet, S (2021) Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. *The Lancet Respiratory Medicine*, **9**(3), 295–304. doi:10.1016/S2213-2600(20)30556-7.
157. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial | SpringerLink (n.d.). Retrieved April 26, 2023, from <https://link.springer.com/article/10.1186/s12879-020-05507-4>
158. The Writing Committee for the REMAP-CAP Investigators (2020) Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA*, **324**(13), 1317–1329. doi:10.1001/jama.2020.17022.
159. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2105911>
160. Therapeutic efficacy of macrolides in management of patients with mild COVID-19 | Scientific Reports (n.d.). Retrieved April 26, 2023, from <https://www.nature.com/articles/s41598-021-95900-z>
161. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial - The Lancet (n.d.). Retrieved April 26, 2023, from [https://www.thelancet.com/article/S0140-6736\(21\)01203-4/fulltext](https://www.thelancet.com/article/S0140-6736(21)01203-4/fulltext)
162. Thieme E-Journals - Thrombosis and Haemostasis / Full Text (n.d.). Retrieved April 26, 2023, from <https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1414-5216>
163. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2030340>
164. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia | NEJM (n.d.). Retrieved April 26, 2023, from <https://www.nejm.org/doi/full/10.1056/NEJMoa2101643>
165. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study | Antimicrobial Agents and Chemotherapy (n.d.). Retrieved April 26, 2023, from <https://journals.asm.org/doi/full/10.1128/AAC.00350-21>
166. Tomazini, BM, Maia, IS, Cavalcanti, AB, ... COALITION COVID-19 Brazil III Investigators (2020) Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe

- Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. *JAMA*, **324**(13), 1307–1316. doi:10.1001/jama.2020.17021.
167. Udhwadia, ZF, Singh, P, Barkate, H, ... Tandon, M (2021) Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. *International Journal of Infectious Diseases*, **103**, 62–71. doi:10.1016/j.ijid.2020.11.142.
168. Vallejos, J, Zoni, R, Bangher, M, ... Aguirre, MG (2021) Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infectious Diseases*, **21**(1), 635. doi:10.1186/s12879-021-06348-5.
169. Vanassche, T, Engelen, MM, Van Thillo, Q, ... DAWn consortium members (2020) A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. *Trials*, **21**(1), 1005. doi:10.1186/s13063-020-04878-y.
170. Wang, Y, Zhang, D, Du, G, ... Wang, C (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*, **395**(10236), 1569–1578. doi:10.1016/S0140-6736(20)31022-9.
171. Weehuizen, JM, and Hoepelman, AIM (2020) An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)—Protocol publication. *European Journal of Clinical Investigation*, **50**(7), e13297. doi:10.1111/eci.13297.
172. Xia, S, Duan, K, Zhang, Y, ... Yang, X (2020) Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *JAMA*, **324**(10), 951–960. doi:10.1001/jama.2020.15543.
173. Xia, S, Zhang, Y, Wang, Y, ... Yang, X (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *The Lancet Infectious Diseases*, **21**(1), 39–51. doi:10.1016/S1473-3099(20)30831-8.
174. Yahav, D, Rozen-Zvi, B, Mashraki, T, ... Rahamimov, R (2021) Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). *BMJ Open*, **11**(10), e055611. doi:10.1136/bmjopen-2021-055611.
175. Yang, S, Li, Y, Dai, L, ... Gao, GF (2021) Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. *The Lancet Infectious Diseases*, **21**(8), 1107–1119. doi:10.1016/S1473-3099(21)00127-4.
176. Zhang, Y, Zeng, G, Pan, H, ... Zhu, F (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases*, **21**(2), 181–192. doi:10.1016/S1473-3099(20)30843-4.

177. Zhao, H, Zhang, C, Zhu, Q, ... Wang, G (2021a) Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. *International Immunopharmacology*, **97**, 107702. doi:10.1016/j.intimp.2021.107702.
178. Zhao, H, Zhu, Q, Zhang, C, ... Wang, G (2021b) Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. *Biomedicine & Pharmacotherapy*, **133**, 110825. doi:10.1016/j.biopha.2020.110825.
179. Zheng, F, Zhou, Y, Zhou, Z, ... Gong, G (2020) SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial. *International Journal of Infectious Diseases*, **99**, 84–91. doi:10.1016/j.ijid.2020.07.053.
180. Zhu, F-C, Guan, X-H, Li, Y-H, ... Chen, W (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *The Lancet*, **396**(10249), 479–488. doi:10.1016/S0140-6736(20)31605-6.

RCT protocol publication only (n=23)

1. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial - Brett L Houston, Patrick R Lawler, Ewan C Goligher, Michael E Farkouh, Charlotte Bradbury, Marc Carrier, Vlad Dzavik, Dean A Fergusson, Robert A Fowler, Jean-Phillippe Galanaud, Peter L Gross, Emily G McDonald, Mansoor Husain, Susan R Kahn, Anand Kumar, John Marshall, Srinivas Murthy, Arthur S Slutsky, Alexis F Turgeon, Scott M Berry, Robert S Rosenson, Jorge Escobedo, Jose C Nicolau, Lindsay Bond, Bridget-Anne Kirwan, Sophie de Brouwer, Ryan Zarychanski, 2020 (n.d.). Retrieved April 26, 2023, from https://journals.sagepub.com/doi/full/10.1177/1740774520943846?casa_token=_OfMKIH0Vx8AAA%3AKfkzuZemUE1Z_vw2kj6U5xnF9CmbP7ID0b1bjejW2lbuPZPEutE7Puka_pPi68s919IoLC2LsfjIF8OG
2. BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial) | *BMJ Open* (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/10/e052101.abstract>
3. Bosi, E, Bosi, C, Rovere Querini, P, ... Bregni, M (2020) Interferon β -1a (IFN β -1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. *Trials*, **21**(1), 939. doi:10.1186/s13063-020-04864-4.
4. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study - Kosiborod - 2021 - Diabetes, Obesity and Metabolism - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14296>
5. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study | SpringerLink (n.d.). Retrieved April 26, 2023, from <https://link.springer.com/article/10.1186/s13063-020-04478-w>
6. Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME

COVID-19 study) | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/9/e053325.abstract>

7. Gyselinck, I, Liesenborghs, L, Landeloos, E, ... on behalf of the DAWn-Azithro consortium (2021) Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial. *Trials*, **22**(1), 126. doi:10.1186/s13063-021-05033-x.

8. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STERIOD 2) trial: Protocol and statistical analysis plan - Munch - 2021 - Acta Anaesthesiologica Scandinavica - Wiley Online Library (n.d.). Retrieved April 26, 2023, from https://onlinelibrary.wiley.com/doi/abs/10.1111/aas.13795?casa_token=7oF03IIWpYoAAAAA:ATsK1V165tEvACckdcAQ1XmAugoGALlyT9_-dUsLqKDr2NQunk82BAEN3_nDHHo3nwOj-mUDV9aJNqlo

9. Iturriaga, C, Eiffler, N, Aniba, R, ... Garcia-Huidobro, D (2021) A cluster randomized trial of interferon β -1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). *BMC Infectious Diseases*, **21**(1), 814. doi:10.1186/s12879-021-06519-4.

10. Lasky, JA, Fuloria, J, Morrison, ME, ... Melemed, A (2021) Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. *Advances in Therapy*, **38**(1), 782–791. doi:10.1007/s12325-020-01539-z.

11. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STERIOD) trial—Protocol and statistical analysis plan - Petersen - 2020 - Acta Anaesthesiologica Scandinavica - Wiley Online Library (n.d.). Retrieved April 26, 2023, from https://onlinelibrary.wiley.com/doi/abs/10.1111/aas.13673?casa_token=RdGuQ__RH2QAAAAA:8kQABtChXgnvNBLzDCVNU6julZFaeDNjDWu9JtLsnJidu5PKKW-rehSRfhqqlNpwzKsY8EOrdqqa9uVE

12. Mansour, E, Bueno, FF, de Lima-Júnior, JC, ... Velloso, LA (2021) Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial. *Trials*, **22**(1), 71. doi:10.1186/s13063-021-05027-9.

13. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19 | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/4/e047495.abstract>

14. New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial) | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/8/e045190.abstract>

15. Okumuş, N, Demirtürk, N, Çetinkaya, RA, ... Taşkın, G (2021) Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. *BMC Infectious Diseases*, **21**(1), 411. doi:10.1186/s12879-021-06104-9.

16. Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol | BMJ Open (n.d.). Retrieved April 26, 2023, from <https://bmjopen.bmj.com/content/11/5/e047069.abstract>

17. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol - Cohen - 2020 - The Journal of Clinical Hypertension - Wiley Online Library (n.d.). Retrieved April 26, 2023, from <https://onlinelibrary.wiley.com/doi/full/10.1111/jch.14011>

18. Sivapalan, P, Ulrik, CS, Lappere, TS, ... Jensen, J-US (2020) Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. *Trials*, **21**(1), 867. doi:10.1186/s13063-020-04795-0.
19. Tan, DHS, Chan, AK, Jüni, P, ... McGeer, A (2021) Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. *Trials*, **22**(1), 224. doi:10.1186/s13063-021-05134-7.
20. Tavares, M, Farraia, M, Silva, S, ... Moreira, A (2021) Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial. *Porto Biomedical Journal*, **6**(2), e134.1-5. doi:10.1097/j.pbj.0000000000000134.
21. Vanassche, T, Engelen, MM, Van Thillo, Q, ... DAWn consortium members (2020) A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. *Trials*, **21**(1), 1005. doi:10.1186/s13063-020-04878-y.
22. Weehuizen, JM, and Hoepelman, AIM (2020) An open-label cluster-randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC)—Protocol publication. *European Journal of Clinical Investigation*, **50**(7), e13297. doi:10.1111/eci.13297.
23. Yahav, D, Rozen-Zvi, B, Mashraki, T, ... Rahamimov, R (2021) Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). *BMJ Open*, **11**(10), e055611. doi:10.1136/bmjopen-2021-055611.

RCT Finding publication + Protocol publication (n=10)

1. "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | NEJM." Accessed April 26, 2023. <https://www.nejm.org/doi/full/10.1056/nejmoa2016638>.
2. Ader, Florence. "Protocol for the DisCoVeRy Trial: Multicentre, Adaptive, Randomised Trial of the Safety and Efficacy of Treatments for COVID-19 in Hospitalised Adults." *BMJ Open* 10, no. 9 (September 1, 2020): e041437. <https://doi.org/10.1136/bmjopen-2020-041437>.
3. Butler, Christopher C, Jienchi Dorward, Ly-Mee Yu, Oghenekome Gbinigie, Gail Hayward, Benjamin R Saville, Oliver Van Hecke, et al. "Azithromycin for Community Treatment of Suspected COVID-19 in People at Increased Risk of an Adverse Clinical Course in the UK (PRINCIPLE): A Randomised, Controlled, Open-Label, Adaptive Platform Trial." *The Lancet* 397, no. 10279 (March 20, 2021): 1063–74. [https://doi.org/10.1016/S0140-6736\(21\)00461-X](https://doi.org/10.1016/S0140-6736(21)00461-X).
4. Casey, Jonathan D., Nicholas J. Johnson, Matthew W. Semler, Sean P. Collins, Neil R. Aggarwal, Roy G. Brower, Steven Y. Chang, et al. "Rationale and Design of ORCHID: A Randomized Placebo-Controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19." *Annals of the American Thoracic Society* 17, no. 9 (September 2020): 1144–53. <https://doi.org/10.1513/AnnalsATS.202005-478SD>.
5. "Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network." Accessed April 26, 2023. <https://jamanetwork.com/journals/jama/article-abstract/2775280>.
6. "Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Critical Care Medicine | JAMA | JAMA Network." Accessed April 26, 2023. <https://jamanetwork.com/journals/jama/article-abstract/2777829>.
7. "SciELO - Brazil - Justificativa e Delineamento Do Estudo 'Tocilizumabe Em Pacientes Com COVID-19 Moderado a Grave: Estudo Aberto, Multicêntrico, Randomizado, Controlado' (TOCIBRAS) Justificativa e Delineamento Do Estudo 'Tocilizumabe Em Pacientes Com COVID-19 Moderado a Grave: Estudo Aberto, Multicêntrico, Randomizado, Controlado' (TOCIBRAS)." Accessed April 26, 2023. <https://www.scielo.br/j/rbti/a/KzmQ33srPtCkV445mjhPznJ/abstract/?lang=en>.
8. "Therapeutic versus Prophylactic Anticoagulation for Patients Admitted to Hospital with COVID-19 and Elevated D-Dimer Concentration (ACTION): An Open-Label, Multicentre, Randomised, Controlled Trial - The Lancet." Accessed April 26, 2023. [https://www.thelancet.com/article/S0140-6736\(21\)01203-4/fulltext](https://www.thelancet.com/article/S0140-6736(21)01203-4/fulltext).
9. Tomazini, Bruno M., Israel S. Maia, Alexandre B. Cavalcanti, Otavio Berwanger, Regis G. Rosa, Viviane C. Veiga, Alvaro Avezum, et al. "Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial." *JAMA* 324, no. 13 (October 6, 2020): 1307–16. <https://doi.org/10.1001/jama.2020.17021>.
10. Wang, Yeming, Dingyu Zhang, Guanhua Du, Ronghui Du, Jianping Zhao, Yang Jin, Shouzhi Fu, et al. "Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial." *The Lancet* 395, no. 10236 (May 16, 2020): 1569–78. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9).

Supplementary file 3: List of consortia of funders

Consortia of funders	Frequency	Percentage
Academia, NGO and public funding	3	8.6%
Academia, Private and public funding	1	2.9%
Commercial and NGO	1	2.9%
Commercial and public funding	2	5.7%
Commercial, Academic	1	2.9%
Commercial, Academic, Public funding	1	2.9%
NGO and academia	7	20%
NGO and Private	1	2.9%
NGO, Public funding	1	2.9%
NGO, Public funding and Commercial	1	2.9%
Private and NGO	1	2.9%
Private and NGO and Academic	1	2.9%
Private, NGO, and Public funding	1	2.9%
Public and private funding	3	8.6%
Public funding and academia	1	2.9%
Public funding and commercial	3	8.6%
Public funding and NGO	4	11.4%
Public, Private and NGO	1	2.9%
Public, Private, NGO and Academia	1	2.9%
Total	35	100%

Supplementary file 4: Analysis of geographical distribution single and multi-country RCTs

Single country RCTs

Country name	Frequency	Percentage
Argentina	1	1%
Australia	2	1%
Bangladesh	1	1%
Belgium	3	2%
Brazil	17	11%
Canada	3	2%
Chile	1	1%
China	27	18%
Colombia	2	1%
Denmark	1	1%
Egypt	8	5%
France	4	3%
India	6	4%
Indonesia	1	1%
Iran	22	14%
Iraq	1	1%
Italy	3	2%
Japan	1	1%
Lebanon	1	1%
Mexico	4	3%
Netherlands	2	1%
Norway	2	1%
Unknown	1	1%
Portugal	1	1%
Russia	2	1%

Saudi Arabia	1	1%
South Africa	2	1%
Spain	2	1%
Turkey	3	2%
United Kingdom	8	5%
United States	19	12%
Unknown	1	1%
Total	153	100%

Multi-country RCTs

Country name	Frequency	Percentage
Argentina	4	3%
Australia	3	2%
Austria	2	1%
Bahrain	1	1%
Begium	4	3%
Brazil	8	5%
Canada	6	4%
Chile	1	1%
China	4	3%
Colombia	1	1%
Croatia	1	1%
Denmark	6	4%
Egypt	1	1%
France	5	3%
Germany	7	5%
Greece	1	1%
Hungary	1	1%
India	5	3%
Ireland	1	1%
Italy	5	3%
Japan	3	2%
Jordan	1	1%
Kenya	1	1%
Luxembourg	1	1%
Mexico	8	5%

Moldova	1	1%
Monaco	1	1%
Netherlands	4	3%
New Zealand	1	1%
Peru	2	1%
Poland	1	1%
Portugal	3	2%
Republic of Korea	3	2%
Republic of Romania	1	1%
Russia	1	1%
Singapore	4	3%
South Africa	3	2%
Spain	9	6%
Sweden	3	2%
Switzerland	4	3%
Turkey	1	1%
United Arab Emirates	1	1%
United Kingdom	10	7%
United States	18	12%
Total	152	100%

For multi-country trials, we listed individual countries and summed-up frequency distribution of RCTs for each country. This yielded multi-country trials conducted across 44 individual countries with an overestimation of frequency of RCTs to 152.

Supplementary file 4: WHO-region wise distribution of RCTs

WHO regions	Single country (N)	Multi country (N)	Total (N)	Percentage
Unknown	1	0	1	0.3%
Region of the Americas	47	47	94	30.8%
Western pacific	30	18	48	15.7%
European Region	31	74	105	34.4%
Eastern Mediterranean	34	4	38	12.5%
African Region	2	4	6	2%
South-East Asia	8	5	13	4.3%
			305	100%

Single and multi-country trials were added to arrive at total frequency for each WHO regions